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Abstract 
Mycolactone is a polyketide macrolide lipid-like secondary metabolite synthesised by 
Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU), and is the only virulence factor for 
this pathogen identified to date. Prolonged exposure to high concentrations of mycolactone is 
cytotoxic to diverse mammalian cells (albeit with varying efficiency), whereas at lower doses it has a 
spectrum of immunosuppressive activities. Combined, these pleiotropic properties have a powerful 
influence on local and systemic cellular function that should explain the pathophysiology of BU 
disease. The past decade has seen significant advances in our understanding of the molecular 
mechanisms underlying these effects in a range of different cell types. This review will focus on the 
current state of our knowledge of mycolactone function, its molecular and cellular targets, seeking 
to identify commonalities between the different functional and cellular systems. Since mycolactone 
influences fundamental cellular processes (cell division, cell death, and inflammation), getting to the 
root of how mycolactone achieves this could have profound impact on our understanding of 
eukaryotic cell biology. 
Introduction 
BU is a chronic necrotising skin ulcer caused by infection with the environmental opportunistic 
pathogen, Mycobacterium ulcerans. While the mechanism by which infection is acquired from the 
environment is still controversial (person to person transmission does not occur except in one 
reported case of mechanical skin breakage [biting]), what is clear is that the production of 
mycolactone by the bacilli is essential to the pathophysiology of the disease. Mycolactone has been 
shown to cause the two determining features of the ulcers - the cellular cytotoxicity and the 
pronounced immunosuppression - which act together to drive the progressive ulceration and 
persistent infections seen in patients. There are many excellent reviews of BU disease pathogenesis 
[1, 2], treatment [3] and transmission [4] as well as M. ulcerans microbiology [5, 6] in the literature - 
this review will therefore focus specifically on the cellular actions of mycolactone on eukaryotic 
(host) cells, and recent advances in our understanding of the molecular mechanism by which 
mycolactone mediates these effects. 
Mycolactone 
The existence of a factor that contributed to the virulence of M. ulcerans was postulated as long ago 
as 1965 [7], but was first assumed to be a secreted protein toxin. Sterile filtrates of liquid cultures 
were shown to induce rounding up, detachment and death of L929 fibroblasts in culture [8], and also 
to inhibit the proliferation of T cells and phagocytosis by murine macrophages [9]. The cytotoxic 
activity and an ability to suppress cytokine production was subsequently shown to reside in the 
alcohol soluble lipids (ASLs) extracted from M. ulcerans culture supernatants [10, 11]; but it wasn't 
until 1999 that mycolactone was isolated to purity by Pamela Small's group [12]. In contrast to initial 
expectations, it is now clear that mycolactone largely resides in the extracellular matrix (biofilm) that 
forms around growing bacterial colonies/clusters [13]. 
Mycolactone is a polyketide lactone (Figure 1), consisting of a 12-membered lactone core and two 
polyketide side chains [12]. As such, it is lipid-like in its characteristics and highly hydrophobic. The 
most virulent strains of M. ulcerans makes a 3:2 ratio of mycolactone A/B (Z-/E- isomers of the C4-C5 
bond in the long polyketide side chains) and most research into the biological functions of 
mycolactone has focussed on this. Experimental investigation has been facilitated in recent years by 
the availability of synthetic mycolactone [14] with which to carry out biological assays. So far, the 
biological activity of the biological synthetic compound appears to be identical to that of the purified 
natural A/B form ([15] and Hall and Simmonds unpublished). However, a number of naturally 
occurring variants of mycolactone are produced by clinical isolates from geographically diverse areas 
as well as other non-pathogenic mycolactone-producing mycobacteria (MPM) (Figure 1). Indeed 
most strains of M. ulcerans make a range of mycolactone-like molecules [16]. Each of these 
mycolactones contain the lactone ring and vary by the length of the side chain, and the location of 
hydroxyl groups and double bonds within it and they all have differing abilities to induce cellular 
cytotoxicity and suppress cytokine production (see below, and reviewed in [17, 18]). This implies 
that the biological function is conferred largely by the long polyketide side chain, and this was 
confirmed in a recent study where synthetic mycolactones A/B, C and F had differing LC50 values, and 
loss of this side chain renders the compound effectively inert [15]. On the other hand, modifications 
of the short polyketide chain had a less profound influence over cytotoxic activity [15]. 
Mycolactone production is due to the giant (174Kb) plasmid pMUM [19] that is present in all MPM. 
There is still a paucity of experimental data relating to the timing, regulation and extent of 
mycolactone production for M ulcerans bacilli. The mls genes encoded in pMUM have been reported 
to have a strong sigA type promoter that is constitutively expressed during planktonic monoculture 
under laboratory conditions [20]. But how this relates to expression in its environmental niche (itself 
not clearly defined) or during different stages of clinical ulcers is not known. What is clear, however, 
is that during antibiotic treatment of patients with advanced ulcers, a non-inflammatory 
immunohistochemistry reverts to a granulomatous pattern more similar to that seen in other 
mycobacterial infections (such as M. tuberculosis, M. leprae and M. marinum M), possibly suggesting 
that rifampicin/streptomycin are able to switch off mycolactone production as part of the 
mycobacteriocidal activity [21]. On the other hand, mycolactone has been successful isolated from 
ulcer exudates of patients who have completed a sterilising course of antibiotic therapy [22] and also 
persists in experimental infections [23]. 
It is assumed that mycolactone accesses mammalian cells by means of passive diffusion due to its 
hydrophobic nature. Bodipy-labelled mycolactone has been detected in the cytosol of cells within 2 
minutes of exposure, but interestingly is excluded from the nucleus [24, 25]. Other in vivo 
experiments have demonstrated that mycolactone can diffuse away from the site of injection and 
can access all bodily compartments with the exception of the brain [26]. In a patient study, 
mycolactone could be detected in the serum of 3 out of 6 BU patients prior to starting antibiotic 
therapy [22]. Thus is seems that mycolactone can have wide-reaching systemic, yet not universal, 
effects. 
Cytotoxic activity 
At high doses (usually considered to be above 1µg/ml, around 1.3µM) and/or prolonged exposure 
times (>24-48 hours), mycolactone is generally cytotoxic to mammalian cells. The most sensitive 
cells identified to date are L929 murine fibroblasts and these are frequently used as reporter cells. 
DNA content analysis showed that mycolactone induces cell cycle arrest at G1/G0 [12]. The cells also 
undergo cytoskeletal rearrangements and become apoptotic. Interestingly, different types of cells 
show different susceptibilities to mycolactone-induced cytotoxicity. For instance, purified human 
monocytes [27] show no significant reduction in viability after 24 hours, whereas immature dendritic 
cells (DCs) are relatively more sensitive after 48 hours [28]. Even prolonged (>24 hour) exposure of 
PBMCs [29], mature DCs [28], Jurkat T cells [29] and myeloid cell lines, such as J774 (human 
macrophage-like) [30], RAW264.7 (murine macrophage; Hall and Simmonds, unpublished) and CLC 
(adherent carp monocytic) cells [31] causes only minimal cytotoxicity, growth inhibition or apoptosis.  
It is also interesting to consider cytotoxicity in the context of infected skin, and different groups have 
now investigated the sensitivity of myocytes, keratinocytes, adipocytes, fibroblasts and Schwann 
cells to mycolactone [32-35]. All of these cells can be killed by mycolactone, although adipocytes in 
particular seem to require extended exposure times even to see small levels of necrosis [35].  The 
neurotoxicity has been a suggested mechanism for the painlessness of BU ulcers although the 
connection between cell cycle arrest and toxicity is unclear [33].  Even though the keratinocytes at 
the basal layer of epidermis are rapidly dividing in human skin and are reportedly sensitive to 
mycolactone, the epidermis is often observed to be undergoing hyperplasia during BU [36]. On the 
other hand, relatively resistant adipocytes do not divide beyond puberty but are killed in BU, 
providing the classic "ghost-cell" appearance of coagulative necrosis in histopathology indicating 
that they must be susceptible to mycolactone's effects, either directly or indirectly. How these 
different in vitro and in vivo phenomena are related is a highly interesting question, and the 
mechanism of cell death as a consequence of mycolactone exposure in infections appears to be 
more complex than simply a matter of cell cycle arrest. 
In fact, recent work by Caroline Demangel's group has shed light on a mechanism of mycolactone 
induced cell death  [37]. Here, low doses of mycolactone were shown to cause cells to rapidly form 
filopodia; clusters of actin bundles associated with wound healing and cell-cell interactions. This was 
found to be due to mycolactone-dependent enhancement of actin polymerisation following its 
binding to the GTPase domain of the Wiskott-Aldrich syndrome Protein (WASP) family of proteins. 
The inappropriate activation of WASP and relocalisation of the actin nucleating complex Arp2/3 are 
thought to explain the well characterised cytoskeletal rearrangement in mycolactone treated cells. 
These were associated with loss of cell adhesion and e-cadherin-dependent tight junctions which 
could be partially restored by the addition of the WASP inhibitor, wiskostatin. Indeed e-cadherin 
itself appears to be down regulated by mycolactone ([37] Table 1). It therefore appears that, at least 
in vitro, cell death is related to anoikis, i.e. apoptosis due to detachment. 
Immunosuppressive activity 
One of the most striking features of BU histopathology sections is abundant foci of extracellular acid-
fast bacilli in the absence of an inflammatory infiltrate. Instead, mononuclear cells are found the 
periphery of the infection but not close to the bacilli, suggesting the signals required to access the 
infection are missing [26, 38, 39]. It is now generally accepted that mycolactone is the 
immunosuppressive factor. Since this immunosuppression is so central to the body's inability to clear 
the infection (although it should be noted that this is not always the case - some patients do 
spontaneously heal and this is associated with a delayed-type hypersensitivity response [40]) much 
research attention has focussed on this area in the last decade. Immunosuppressive doses of 
mycolactone are generally lower than cytotoxic doses on the same cell type, and are certainly faster 
acting. For instance, primary human monocytes begin to produce TNF within 40 minutes of exposure 
to an inflammatory agent and mycolactone effectively obliterates this at a tenth of the cytotoxic 
dose [27]. 
Mycolactone can suppress both innate and adaptive immune responses in patients and in 
experimentally infected mice. Mycolactone is also able to suppress innate responses by restricting 
many of the functions of tissue resident macrophages. Like other mycobacterial infections, M. 
ulcerans can be phagocytosed by macrophages in the early stages of infection [41], presumably 
escaping digestion by preventing phagolysosome formation similarly to M. tuberculosis. Over short 
time periods and at low MOIs it can proliferate inside murine macrophages, until mycolactone 
causes the apoptosis/necrosis of the macrophages and the release of the bacilli into the intercellular 
space [39]. Despite this, it has been shown in vitro that wild type strains of M. ulcerans are not 
phagocytosed as effectively as mycolactone-negative strains and exogenous mycolactone has the 
ability to complement this activity [41, 42].  
One of the other key events that would normally occur upon phagocytosis of a microbe is activation 
by pathogen-associated molecular patterns (PAMPs) - including stimulation of Toll-like receptors 
[TLRs] and the NLRP3 inflammasome - resulting in intracellular signalling cascades that result in a 
rapid, profound and controlled inflammatory response, including the production of cytokines and 
chemokines to recruit other inflammatory cells to the site of infection. However, cells exposed to 
mycolactone-producing strains of M. ulcerans secrete dramatically less TNF than those encountering 
mycolactone-negative strains [43]. Purified mycolactone profoundly inhibits the ability of 
monocytes, macrophages, T cells and DCs to do this [10, 27, 43, 44]. Furthermore, the production of 
other cytokines and chemokines, (including IL-6, IL-8, IL-10 and IP-10) is also dramatically reduced in 
both primary human monocytes and macrophages, as is expression of the pro-inflammatory 
mediator cyclooxygenase-2 (COX-2) (Table 1; [27] and Hall and Simmonds, unpublished). Failure to 
produce cytokines and chemokines at the site of infection is considered a likely explanation for the 
lack of an inflammatory infiltrate close to bacilli, with the peripheral infiltrate indicating the limit of 
biologically active doses of mycolactone [2]. However, the technical expertise to measure or detect 
such low levels of mycolactone in situ is still lacking. 
In addition to inhibiting macrophage function, mycolactone also inhibits DC maturation, as 
determined by the maturation marker CD83 (see Table 1), and a lack of the expected upregulation of 
the costimulatory molecules CD80 and CD40 in response to PAMPs such as lipopolysaccharide (LPS) 
[28]. In addition, DC chemokine production is suppressed, principally affecting IP-10, MCP-1 and 
MIP-1α [28]. This may explain the anergy that has been reported in patients, where their T cells no 
longer respond to mycobacterial antigens after exposure [45], and contribute to the reduced 
Th1/Th2/Th17 responses seen in whole blood-restimulations [44]. In addition to inhibiting the 
costimulatory and migratory function of DCs, and therefore indirectly affecting T cell activation, T 
cells themselves are also directly sensitive. Low doses of mycolactone directly block the mitogen- 
and CD3/CD28-depedent production of IL-2, IL-4, IL-8, IL-10, IL-17, IFNγ and MIP-1β from CD4+ T 
cells [44]. Furthermore, lymphocyte homing to peripheral lymph nodes is inhibited due to a down-
regulation of L-selectin and LFA-1 on the surface of T cells [46]. 
Mechanism underlying mycolactone-dependent inhibition of protein production. 
It is predicted that the proteins affected by mycolactone may share an underlying mechanism of 
production that could explain their co-regulation. The gene regulatory networks of many 
inflammatory mediators, including cytokines, chemokines and some PAMP-induced costimulatory 
molecules have many components in common, making them attractive targets for investigation. 
Transcriptional regulation by the NFκB and IRF transcription factors is the most widely studied 
example, as well as mRNA stabilisation mediated by p38 MAPK and AU-rich elements (AREs) in the 3' 
UTRs of inflammatory genes [47, 48]. Furthermore, some cytokines such as TNFα are translationally 
derepressed by LPS by a mechanism that is also partially dependent on AREs but is still not yet fully 
understood [49]. Production of mature TNFα and IL-1β are additionally dependent on cleavage of 
pro-proteins by TACE (tumour necrosis factor-α-converting enzyme) and caspase-1 (in the NRLP3 
inflammasome), respectively [50, 51]. 
Early work on the mechanism of suppression by mycolactone was a carried out in Jurkat T cells using 
ASLs and focussed on the suppression of IL-2 production [10]. In this cell line, mycolactone strongly 
inhibited the activation of NFκB following TNFα stimulation, which led to the initial assumption that 
this was a generalisable mechanism, even though these authors found no effect on NFκB activation 
in other different model systems (PMA-induced in Jurkat cells, IL-1 induced in HeLa cells and LPS 
induced in RAW264.7 cells) [10]. Indeed the effect of mycolactone on steady state IL-2 mRNA levels 
turns out to be dependent on the stimulus, being substantially reduced during the CD3/CD28 
response and enhanced for PMA/ionomycin [29]. More recently transcriptional profiling of primary 
human T cells found no significant changes in mRNA level [46]. The situation is similar in myeloid 
cells since a detailed investigation of the effect of mycolactone on the LPS-dependent upregulation 
of TNFα, IL-6 and COX-2 showed that while protein production is completely ablated by low 
immunosuppressive (non-cytotoxic) doses of mycolactone, the steady state induced mRNA levels are 
not affected or are again enhanced in the case of TNFα [27]. This is true for primary human 
monocytes [27], RAW264.7 cells [41], primary human macrophages and HeLa cells (Hall and 
Simmonds unpublished). Thus it seems that, with the exception of the transformed Jurkat T cell line, 
transcriptional regulation cannot explain the immunosuppression seen in mycolactone-exposed 
cells. 
A detailed investigation in primary human monocytes was the first to propose a post-transcriptional 
mechanism for mycolactone function, probably at the level of translation [27] Analysis of the 
signalling pathways revealed that neither MAPK or NFκB signalling was affected in these cells, and 
neither did the proteins appear to be trapped inside the cells. The enhanced or unaffected 
transcription would also seem to rule out an effect on mRNA stability - indeed even inhibitors such 
as SB203080, which targets p38 MAPK, are only cause partial inhibition of TNF production [52], in 
contrast to the complete block seen following mycolactone exposure. While it is clear that 
mycolactone is acting post-transcriptionally, mycolactone is not a general inhibitor of protein 
production in monocytes, since it does not suppress total protein synthesis. Total incorporation of 
35S-labelled Met/Cys is not altered by the presence of mycolactone [27] and neither are general 
pathways controlling translation: mycolactone does not affect phosphorylation of the mammalian 
target of rapamycin complex 1 [MTORC1] targets eIF4E or p70s6 kinase or the endoplasmic 
reticulum stress response marker eIF2α [27]. This finding was later confirmed in T cells [29]. Thus it 
seems that mycolactone is selectively targeting a subset of genes for control. One obvious candidate 
for mediating such gene-selective control would be microRNAs but there is little evidence to support 
this. A small yet significant decrease in let-7b levels has been observed in T cells exposed to 
mycolactone. Surprisingly, inhibition of let-7b caused a decrease in L-selectin mRNA and 
overexpression increased it, suggesting that L-selectin is not a direct target of let-7b (since the 
opposite pattern would have been expected). However the findings were not confirmed at the 
protein level. Our group is currently investigating translational and post-translational mechanisms of 
protein production inhibition. 
Conclusion 
Taken together, the loss of protein production by key players in the immune response and cellular 
adhesion would appear to be driving the immunosuppression and tissue necrosis in BU (Table 1). 
Indeed, when all available literature are surveyed, only three proteins could be identified that are 
upregulated by mycolactone (Table 2); the chemokine receptor CCR7 [46] and two muscle-specific 
E3 ubiquitin ligases (MuRF-1 and Atrogin-1)[34]. Of course there are many proteins which escape 
mycolactone-dependent regulation (notably constitutive expression of actin, CD28, p38 MAPK and 
eIF2α and also the LPS-dependent resynthesis of IκBα, Table 2) since total cellular protein 
production rates are not suppressed [27]. However, it is currently unclear how the suppression of 
constitutively expressed proteins such as e-cadherin and CD3 fits with our current models of 
mycolactone function. While the recent finding of a direct interaction between mycolactone and 
WASP is exciting, it would not appear to explain the inhibition of cytokine production since 
wiskostatin treatment does not reverse the action of mycolactone as expected (Hall & Simmonds, in 
preparation). Instead, the cellular compartments of the sensitive and insensitive proteins may be 
informative when considering a unifying mechanism for this fascinating pleiotropic molecule. 
 Table 1 Proteins shown to be down-regulated by mycolactone 
Protein 
downregulated Cell Type Function Ref 
Membrane 
proteins    
CD3 T cell TCR signal transduction [29] 
CD25 DC IL-2 receptor α chain, DC maturation marker [28] 
CD40 (partial) DC Co-stimulatory protein [28] 
CD62-L T cell Adhesion, T cell homing [46] 
CD80 (partial) DC Co-stimulatory protein [28] 
CD83 DC Dendritic maturation marker [28] 
CD86 DC Co-stimulatory protein [28] 
e-Cadherin HeLa Adhesion molecule [37] 
LFA-1 T cell Adhesion, T cell homing [46] 
MHCII DC Antigen presentation molecule [28] 
T cell receptor T cell Antigen recognition [29] 
Cytokines    
IL-1β (partial) Mo  Mφ  DC Cytokine (proinflammatory) [27, 28] 
IL-2 T cell Cytokine (T cell proliferation and differentiation) [10, 26, 29, 44] 
IL-4 T cell Cytokine (Th2 responses) [44] 
IL-6 Mφ  Mo  DC Cytokine (proinflammatory) [27, 28] 
IL-10 T cell  Mo  Mφ Cytokine (Anti-inflammatory, Th2 responses) [10, 27] 
IL 12 (partial) DC Cytokine [28] 
IL- 17 T cell Cytokine (proinflammatory) [44] 
Interferon γ T cell Cytokine (proinflammatory) [44] 
TNFα T cell  Mo  Mφ Cytokine (proinflammatory) [10, 27, 43, 44] 
Chemokines    
IL-8 T cell  Mo  Mφ Chemokine  [27, 44] 
IP-10 Mo  Mφ DC Chemokine (reporter for IFNα/β production) [27, 28] 
MCP-1 DC Chemokine [28] 
MIP1α DC Activates granulocytes, chemokine [28] 
MIP1β T cell Activates granulocytes, chemokine [44] 
RANTES DC Chemokine [28] 
Intracellular    
COX-2 Mo Mφ Prostaglandin synthesis [27] 
 
Abbreviations: CD, cluster of differentiation; COX-2, cycolooxygenase-2; DC, dendritic cell; IL, 
interleukin; MCP-1, monocyte chemotactic protein-1; MIP-1α, macrophage inflammatory protein-
1α; Mo, monocytes; Mφ, macrophage RANTES, regulated upon activation normal T cell expressed 
and presumably secreted; TNFα, tumour necrosis factor α 
 Table 2 Proteins known to be unaffected or up-regulated by mycolactone 
Protein unaffected Cell type Function Ref 
Actin Mo, HeLa Cytoskeleton [27, 37] 
CD28 T cell Costimulatory receptor [29] 
eIF2α T cell, Mo Translation initiation [27, 29] 
fyn T cell Signalling molecule [29] 
IκBα Mo Signalling molecule (inhibition of NFκB) [27] 
LAT T cell Signalling molecule [29] 
lck T cell Signalling molecule [29] 
p34 Arp2/3 HeLa Cytoskeletal regulator [37] 
p38 MAPK T cell, Mo Signalling molecule [27, 29] 
PLCγ1 T cell Signalling molecule [29] 
N-WASP HeLa Cytoskeletal regulator [37] 
ZAP70 T cell Signalling molecule [29] 
Protein 
upregulated Cell Type Function Ref 
CCR7 T cell Chemokine receptor [29] 
MuRF-1 Muscle Muscle-specific  E3 ubiquitin ligase [34] 
Atrogin-1 Muscle Muscle-specific  E3 ubiquitin ligase [34] 
  
Abbreviations: CD, cluster of differentiation; DC, dendritic cell; Mo, monocytes; Mφ, macrophage  
 
Figure Legends 
Figure 1 The structure of naturally occurring mycolactones 
The complete structure of mycolactone A/B is shown, which exists in nature as 3:2 ratio  of Z-/E- 
isomers of the C4-C5 bond in the long polyketide side chains. Since it is this long chain that varies 
between geographically diverse clinical isolates (mycolactones A-D) and other non-pathogenic MPM 
(mycolactones E, F and S1, S2), these chains alone are shown. Data from [12, 17, 53-55] 
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